CDMOs that routinely handle highly potent compounds must raise the bar for containment, safety, and industrial hygiene. Diverse capabilities across chemistries, purification technologies, and analytical techniques — combined with the ability to support projects seamlessly from discovery to commercial production — speed the development of complex and unstable highly potent active pharmaceutical ingredients (APIs) and their formulation into safe, approved, high-quality medicines.Read article
More from Curia
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate fro...